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In Western Europe, Hymenoptera venom allergy (HVA) primarily relates to venoms of the
honeybee and the common yellow jacket. In contrast to other allergen sources, only a
few major components of Hymenoptera venoms had been characterized until recently.
Improved expression systems and proteomic detection strategies have allowed the iden-
tification and characterization of a wide range of additional allergens. The field of HVA
research has moved rapidly from focusing on venom extract and single major allergens to
a molecular understanding of the entire “venome” as a system of unique and characteristic
components. An increasing number of such components has been identified, characterized
regarding function, and assessed for allergenic potential. Moreover, advanced expression
strategies for recombinant production of venom allergens allow selective modification of
molecules and provide insight into different types of immunoglobulin E reactivities and
sensitization patterns. The obtained information contributes to an increased diagnostic
precision in HVA and may serve for monitoring, re-evaluation, and improvement of current
therapeutic strategies.
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HYMENOPTERA VENOM ALLERGY
Hymenoptera venom allergy (HVA) is defined as systemic allergic
or anaphylactic reactions that occur in response to stings of insects
of the Hymenoptera order. In central and western Europe, this
involves most commonly stings by yellow jackets and honey bees,
and less frequently stings by hornets or bumble bees. In south-
ern parts of Europe, paper wasps (Polistinae) also play a relevant
role. The prevalence of systemic allergic reactions to Hymenoptera
stings ranges from 0.3 to 3.4% in the general population. The low-
est occurrence is reported in children and the highest in beekeepers
(1). Data extrapolated from hospital admissions and emergency
department visits (2–5) as well as from a national register for ana-
phylaxis (6) suggest that HVA may account for up to one third
of all anaphylactic reactions. The diagnosis of HVA is routinely
based on the clinical history and detection of immunoglobulin
E (IgE)-mediated sensitization by skin testing and/or by in vitro
detection of venom-specific IgE. In addition, cellular test such as
basophil activation test or histamine release test are used to iden-
tify the sensitizing venom in cases in which the routine testing
is not conclusive. Once the diagnosis is confirmed, immunother-
apy with the culprit venom offers a high degree of protection
from future anaphylactic sting reactions ranging from 80 to 84%
Abbreviations: BAT, basophil activation test; CCD, cross-reactive carbohydrate
determinant; CRP, carbohydrate-rich protein; DPP IV, dipeptidyl peptidase IV;
DW, dry weight; ELISA, enzyme-linked immunosorbent assay; Fuc, fucose; GlcNAc,
N -acetylglucosamine; HRP, horseradish peroxidase; IgE, immunoglobulin E; IgG,
immunoglobulin G; Man, mannose; MRJP, major royal jelly protein; MW, molecu-
lar weight; PAGE, polyacrylamide gel electrophoresis; PDGF, platelet derived growth
factor; sIgE, specific immunoglobulin E; VEGF, vascular endothelial growth factor.
in bee venom allergy and 90–95% in yellow jacket venom (YJV)
allergy (1).
For diagnostic as well as for therapeutic purposes, whole venom
preparations are generally used (Figure 1A). All diagnostic sys-
tems that use whole venom preparations are potentially hampered
by IgE cross-reactivity that does not allow a precise distinction
between true double sensitization and cross-reactivity between dif-
ferent venoms. This cross-reactivity may be based on IgE-reactivity
to homologous single venom allergens present in venom of dif-
ferent families or on IgE-reactivity to cross-reactive carbohydrate
determinants (CCD) (7).
Until recently, the limited information on single venom aller-
gens and their unavailability for diagnostic and therapeutic pur-
poses rendered HVA an outmoded field, particularly when com-
pared to the progress made in the molecular understanding of
other forms of allergies.
Recent advances in expression systems and proteomic detection
strategies have allowed the identification and characterization of a
wide range of additional Hymenoptera allergens and have moved
the field rapidly from focusing on whole venoms and single major
allergens to a molecular understanding of the entire “venome”
as a system of unique and characteristic components. Here, we
review the current information on venom allergens in different
Hymenoptera species, their use for reliable diagnostic detection of
HVA as well as their potential role in therapeutic intervention.
HYMENOPTERA VENOM ALLERGENS
Understanding hypersensitivity reactions to venom allergens is
often hampered by complexity of the source material (Figure 1A).
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FIGURE 1 |Venom components and CCD. (A) Representative 2D-gel of
the honeybee venom stained with Coomassie Brilliant Blue G-250
demonstrating the complexity of the venome (kindly provided by Dr. Nico
Peiren, Laboratory of Zoophysiology, Ghent University, Belgium). (B) CCD
sIgE-reactivity of rabbit anti-HRP serum with different Hymenoptera venoms
in immunoblotting. Note the lack of CCD-reactivity in Polistes venom.
(C) Schematic representation of xenobiotic core glycosylation as found in
insects. This carries an additional α 1,3-linked fucose residue compared to
plants having an additional β 1,2-linked xylose residue. (GlcNAc,
N -acetylglucosamine; Man, mannose; Fuc, fucose). (D) Comparison of IgE
antibody levels to glycosylated rApi m 1 (CG) and native purified Api m 1 in
CCD negative HBV allergic patients (n=89). Hatched horizontal and vertical
lines indicate the 0.35 kUA/L cut-off and the hatched diagonal line
represents a 1:1 ratio.
This is best exemplified by the venom allergen components of the
honeybee (Apis mellifera) and the common yellow jacket (Vespula
vulgaris), as they are known to date (Table 1).
The most prominent honeybee venom (HBV) allergens include
phospholipase A2, hyaluronidase, and the basic 26 amino acid
peptide melittin (8), all of which constitute higher abundance pro-
teins with estimated amounts of 12, 2, and 50% of the venom dry
weight (DW), respectively (9). Classical YJV allergens are phos-
pholipase A1, hyaluronidase, and antigen 5 (10), the function of
which remains unknown. These two sets of proteins are found
with modifications throughout most Hymenoptera species and by
far most identified allergens correspond to these protein classes.
In recent years, however significant progress has been made in
identification of novel molecules of lower abundance. For some
the allergic potential had already been described, such as the acid
phosphatase of HBV (Api m 3), however the gene was identified
and recombinantly expressed only recently (8, 11). Moreover, with
the identification of the 100 kDa allergen C of HBV and its YJV
homolog as dipeptidyl peptidase s IV, a novel class of Hymenoptera
venom enzymes could be described (12, 13). In YJV in addition
to the classical hyaluronidase (Ves v 2.0101), an inactive isoform
(Ves v 2.0201), was identified, which seems to be the dominating
isoform in the venom (14). Furthermore, it was demonstrated that
Api m 10 represents a novel major allergen of HBV with potentially
high impact for diagnostic and therapeutic applications (15, 16).
Other IgE-reactive proteins of HBV include a putative protease
inhibitor (17, 18), a protease (19), an esterase, and a peptidase
whose relevance is currently investigated. The newest allergens
are the two major royal jelly proteins (MRJP) 8 and 9 (two iso-
forms of Api m 11) in HBV (20) as well as novel pan-allergens, the
vitellogenins Api m 12, and Ves v 6 (21).
In addition to these components with documented allergenic
nature, recently some other components such as a C1q-like protein
(22), a platelet derived growth factor (PDGF)/vascular endothelial
growth factor (VEGF)-like protein (23), and hexamerin (24) were
identified, the allergenic nature of which still has to be evaluated.
Transcriptomics very recently suggested the presence of an anti-
gen 5 like protein in the venom of winter bees (25). Even the
season (and most likely the climate and geographic region) seem
to have profound impact on the venome. Proteomics revealed
the presence of the antimicrobial peptide apidaecin (25) further
demonstrating that the complexity of the venome is not restricted
to larger proteins. The lower molecular weight (MW) fraction
of the venom contains a variety of peptidic components with
unique biophysical and clinical characteristics. Their contribu-
tions to the sting reaction beyond IgE-reactivity however still need
to be addressed.
By increasing application of advanced proteomic, peptidomic,
and genomic approaches, the venome and thereby the number
of allergens, certainly will significantly increase in the future. The
most recent proteomic analysis of honey bee venom (Figure 1A)
revealed >100 different components (26). Furthermore, another
level of complexity is achieved by the generation of additional
isoforms and post-translational modification. All available data
however suggest that the apparent plasticity of the venome makes
its final definition a never ending story.
As HBV and YJV can be considered prototypic for other
Hymenoptera venoms, their composition is reflected in other
species including the bumble bee (Bombus terrestris and the Amer-
ican B. pennsylvanicus), the venom composition of which closely
resembles that of the honeybee. Bumble bees gained particular
importance for pollination industry workers.
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Table 1 | Overview about the presently known Hymenoptera venom allergens.
Allergen Name/function MW (kDa) % DW Potential
N-glycosylation
Eukaryotic
expression
BEES (Apis mellifera, A. cerana, A. dorsata)
Api m 1, Api c 1, Api d 1 Phospholipase A2 17 12 1 +
Api m 2 Hyaluronidase 45 2 3 +
Api m 3 Acid phosphatase 49 1–2 2 +
Api m 4 Melittin 3 50 0 −
Api m 5 Allergen C/DPP IV 100 <1 6 +
Api m 6 Protease inhibitor 8 1–2 0 +
Api m 7 Protease 39 ? 3 +
Api m 8 Carboxylesterase 70 ? 4 +
Api m 9 Carboxypeptidase 60 ? 4 +
Api m 10 CRP/icarapin 55 <1 2 +
Api m 11.0101 MRJP 8 65 ? 6 +
Api m 11.0201 MRJP 9 60 ? 3 +
Api m 12 Vitellogenin 200 ? 1 +
BUMBLEBEE (Bombus pennsylvanicus, B. terrestris)
Bom p 1, Bom t 1 Phospholipase A2 16 1 −
Bom p 4, Bom t 4 Protease 27 0, 1 −
YELLOW JACKETS (Vespula vulgaris,V. flavopilosa,V. germanica,V. maculifrons,V. pensylvanica,V. squamosa,V. vidua)
Ves v 1, Ves m 1, Ves s 1 Phospholipase A1 35 6–14 0, 0, 2 +
Ves v 2.0101, Ves m 2 Hyaluronidase 45 1–3 4 +
Ves v 2.0201 Hyaluronidasea 45 ? 2 +
Ves v 3 DPP IV 100 ? 6 +
Ves v 5, Ves f 5, Ves g 5, Ves m 5, Ves p 5, Ves s 5, Ves vi 5 Antigen 5 25 5–10 0 +
Ves v 6 Vitellogenin 200 ? 4 +
WHITE-FACED HORNET,YELLOW HORNET (Dolichovespula maculate, D. arenaria)
Dol m 1 Phospholipase A1 34 2 −
Dol m 2 Hyaluronidase 42 2 −
Dol m 5, Dol a 5 Antigen 5 23 0 +
HORNETS (Vespa crabro,V. magnifica,V. mandarinia)
Vesp c 1, Vesp m 1 Phospholipase A1 34 0 −
Vesp ma 2 Hyaluronidase 35 4
Vesp c 5, Vesp ma 5, Vesp m 5 Antigen 5 23 0 −
EUROPEAN PAPERWASPS (Polistes dominula, P. gallicus)
Pol d 1, Pol g 1 Phospholipase A1 34 1 −
Pol d 4 Protease 33 6 −
Pol d 5, Pol g 5 Antigen 5 23 0 −
AMERICAN PAPERWASPS (Polistes annularis, P. exclamans, P. fuscatus, P. metricus)
Pol a 1, Pol e 1 Phospholipase A1 34 0 −
Pol a 2 Hyaluronidase 38 2 −
Pol e 4 Protease ?
Pol a 5, Pol e 5, Pol f 5, Pol m 5 Antigen 5 23 0 +
FIRE ANTS (Solenopsis invicta, S. geminata, S. richteri, S. saevissima)
Sol i 1 Phospholipase A1 35 <1 3 −
Sol i 2, Sol g 2, Sol r 2, Sol s 2 14 0 +
Sol i 3, Sol g 3, Sol r 3, Sol s 3 Antigen 5 26 2 +
Sol i 4, Sol g 4 12 0 −
CRP, carbohydrate-rich protein; DPP IV, dipeptidyl peptidase IV; DW, dry weight; MRJP, major royal jelly protein.
a inactive isoform.
In analogy, venom allergens of diverse other Vespidae species
such as white-faced hornet (Dolichovespula maculata) or the Euro-
pean hornet (Vespa crabro) are fairly similar to those of the
yellow jacket. Allergy to venom of the phylogenetic more dis-
tant paper wasps (Polistinae) is common in North America as
well as in Europe, especially in Mediterranean areas. Important
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Polistes species in Europe are P. dominula and P. gallicus, whereas
in Northern America other species such as P. annularis, P. apachus,
P. exclamans, P. fuscatus, and P. metricus are dominant. In the
last decades, P. dominula has increasingly spread across the North
American continent and central and northern parts of Europe.
The IgE cross-reactivity between European and American Polistes
species is described as rather low because they belong to differ-
ent subgenera. In contrast, cross-reactivity between Polistinae and
Vespinae (Vespula,Dolichovespula, and Vespa) venoms and purified
venom proteins (27) is frequently observed, especially for Vespula
and both American and European Polistes venom (28).
For all these species, only a limited set of allergens has been
identified so far although it is quite likely that all venoms will
contain conserved allergens such as hyaluronidases, dipeptidyl
peptidases, and vitellogenins that in part contribute to molecu-
lar cross-reactivity. Other protein families such as proteases (Api
m 7, Pol d 4) show clear molecular differences and it remains open
if these proteases will be found in all Hymenoptera venoms.
Moreover, it is widely accepted that IgE cross-reactivity between
different insect venoms can be attributed to CCD that are present
on a large number of venom allergens (Figure 1B). The only excep-
tions are apparently venoms of Polistes species that seem to lack
the alpha 1,3-linked fucose (Fuc) residue that is responsible for
IgE-reactivity to CCDs (29).
RECOMBINANT ALLERGENS FOR THE DIAGNOSIS OF HVA
The above mentioned considerations and the entomological diver-
sity of potential culprit insects demand a careful diagnostic
algorithm prior to immunotherapeutic intervention. Diagnosis
of HVA is based on a history of anaphylactic sting reactions,
positive skin test responses, and/or detection of specific IgE to
Hymenoptera venom. Positive results in skin and serological tests
with conventional venom extracts, however, do not always reflect
genuine sensitizations and are frequently caused by clinically irrel-
evant cross-reactive antibodies. Treatment modalities therefore
often include different venoms, resulting in higher costs, increased
risk of side effects, and possible de novo sensitizations. Mole-
cular approaches are increasingly recognized as elegant way to
obtain reliable and detailed diagnostic information. Until recently,
only a very limited number of venom allergens such as Api m 1,
Api m 4, and Ves v 5 was available either as native or recombi-
nant proteins (30, 31). Their use and the possibility to perform
analyses on a molecular level resulted in a clear improvement
of diagnostic precision (32, 33). Inherent problems and general
considerations however apply for the isolation and production of
venom allergens. Even with isolation of high abundance allergens
you run the risk of having contaminating residual components
in the preparation that may distort the picture at a molecular
level.
Applying recombinant technologies, this particular problem
does not exist but difficulties rather lie in the establishment of an
adequate and efficient production system. The efficiency of the
prokaryotic approach is often compromised by the need of exten-
sive folding steps limiting its use to structurally relatively simple
and small molecules. In contrast, eukaryotes such as yeast and
in particular insect and mammalian cells add oligosaccharides,
which are similar but not identical to the glycan of the native
allergen and which influence the folding and the immunoreac-
tivity (34). Although early recognized (34), in the last few years
expression in insect cells was established as appropriate system for
insect venom allergens. The functionality of proteins, the epitope
authenticity, and the correct folding of resulting proteins could be
demonstrated for a large number of allergens (Table 1) (12, 34, 35).
A common problem of in vitro diagnosis of insect venom
allergy using venom extracts are patients with double positive test
results for HBV and YJV that in our HVA patient cohort from the
south west of Germany constitute approximately 45–50% of all
cases. This double positivity may reflect true double sensitization
to HBV and YJV, or may be based on IgE cross-reactivity.
Immunoglobulin E cross-reactivity may be based on com-
mon protein epitopes of homologous allergens of both venoms
as described for hyaluronidases, dipeptidyl peptidases, and the
new 200 kDa vitellogenin allergens. Alternatively, cross-reactivities
can be attributed to IgE antibodies directed against cross-reactive
glyco-epitopes of the allergens (7, 36, 37). This is of particular
importance, since most HBV and YJV allergens are glycoproteins
with one or more of such carbohydrate structures (Table 1).
Causative for the phenomenon of cross-reactivity are IgE anti-
bodies that are directed against an alpha 1,3-linked fuc residue of
the N -glycan core established by insects and plants (Figure 1C).
In plants, additionally a beta 1,2-xylose residue is found at the core
glycan to which IgE also can be directed. Such xenobiotic modifi-
cations represent highly immunogenic epitopes, which can induce
specific immunoglobulin G (IgG) as well as IgE antibodies (38).
CCD-specific IgE antibodies have been reported to be responsi-
ble for more than 50% of double sensitizations to HBV and YJV
(37), complicating the choice of the appropriate therapeutic inter-
vention. The clinical relevance of CCD-reactive IgE antibodies is
controversially discussed, but in the case of insect venom allergy
appears to be low or non-existing. Accordingly, CCD-carrying gly-
coproteins can effect mediator release from basophils but do not
provoke significant responses in individuals with CCD-specific IgE
(39). Nevertheless, anti-CCD IgE represent an undoubted pitfall
of in vitro allergy diagnostics, since they cause multiple reactiv-
ities with any glycosylated plant (food, pollen) or insect venom
allergen and thereby interfere with the detection of clinically rel-
evant sensitization to protein epitopes. A prominent example of
CCD-based interference with diagnostic precision is the honey bee
venom major allergen Api m 1 that carries in its natural form an
alpha 1,3-linked fuc on a N -glycan core structure and thus is reac-
tive with IgE directed against CCDs. Generation of recombinant
forms of Api m 1 that either lack the entire core glycan or only the
1,3 fuc residue, demonstrated a high reliability to detect sensitiza-
tion to the species-specific protein epitopes as compared to nApi
m 1 (Figure 1D) (40).
Molecular diagnosis applying non-glycosylated species-specific
allergens such as Api m 1 and Ves v 5 (41–43) and strategies to
circumvent the presence of CCDs led to a significant advance in
the dissection of true double sensitization versus irrelevant cross-
reactivity. The use of Sf9 insect cells from Spodoptera frugiperda
as expression system results in allergens with functional glycosyla-
tion, proper folding, and complete epitope spectrum but not show-
ing any immunologically detectable CCD-reactivity (Figure 1D).
This phenomenon is obviously based on the specific absence of
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alpha 1,3-core fucosylation (35). Resulting CCD-free engineered
and correctly folded allergens allow for the first time the assessment
of their relevance regardless of their natural glycosylation bypass-
ing complex inhibition analyses. Using CCD-free, correctly folded
Ves v 2.0101 and Ves v 2.0201, we were able to clearly demonstrate
that hyaluronidases – contrary to previous assumptions – do not
play a significant role as major allergens of YJV (35), a fact that
was corroborated by findings of others (44, 45). In contrast, even
for highly glycosylated proteins such as Api m 5, Api m 10, and
Api m 11, a pronounced IgE-reactivity beyond CCDs with clinical
relevance was demonstrated (12, 15, 16, 20).
Another problem of in vitro diagnosis of HVA using venom
extracts are patients with a documented history but negative test
results. A possible reason might be that venom extracts represent
heterogeneous mixtures in which the components are present in
widely varying concentrations and that particular allergens can
be lost or degraded during the processing (15). Alternatively, cou-
pling behavior within the assay system or accessibility of individual
allergens within the extract may be different from the isolated pro-
tein. An excellent example for this kind of discrepancies has been
reported quite recently in patients with YJV allergy (46). Among
patients with a well-documented history of yellow jacket sting
anaphylaxis but negative IgE test results to YJV extract, 84% could
be diagnosed by using recombinant Ves v 5 as allergen. Subse-
quent analysis of a large cohort of YJV allergic patients confirmed
that IgE-reactivity to Ves v 5 was under-represented in the whole
venom extract. This discrepancy could be solved by spiking the
venom extract with rVes v 5, a procedure that was adopted by
one of the manufacturers of these diagnostic extracts (Thermo
Fisher Scientific). These and many other problems can be bypassed
using molecular diagnostics in form of recombinant allergens,
which additionally are available in unlimited amounts and thus
analytically better accessible.
VENOM IMMUNOTHERAPY IN HVA
Specific immunotherapy with the culprit venom (VIT) offers a
high degree of protection from future anaphylactic sting reactions
ranging from 80 to 84% in bee venom allergy and 90–95% in YJV
allergy (1).
The degree of protection induced by VIT is either extrapolated
from patient information on the occurrence and tolerance of field
stings or obtained from clinical data in which patients who are
receiving maintenance VIT undergo a sting challenge in a con-
trolled clinical setting. A most recent study by Rueff et al. that
included more than 1500 patients that had received a sting chal-
lenge, observed a protection rate of 84% for bee VIT and 96% for
yellow jacket VIT (47). Using a logistic regression model to assess
relative risk factors for not being protected, they identified among
others VIT with HBV as one of the highest risk factors (as com-
pared to VIT with YJV) with an odds ratio of 5. This difference
in honeybee versus yellow jacket VIT has been known for decades
and has been suggested to be related to differences in quantities
and qualities of venoms that are injected during the sting. The
recent progress in the molecular characterization of relevant ven-
oms has demonstrated that in particular in HBV low abundance
proteins such as Api m 3, Api m 5, and Api m 10 play an important
and until then underestimated role as allergens (11, 12, 15).
Despite the fact that these allergens are present only in low
quantities, they must be regarded as major allergens since more
that 50% of HBV allergic patients display IgE-reactivity to them
(16). Interestingly, two of these allergens, Api m 3 and Api m
10, while present in the crude venom abstract, are absent or
under-represented in therapeutic venom preparations (15). When
analyzing sensitization profiles in HBV allergic patients, IgE to
Api m 3 and/or Api m 10 was detected in up to 68% and in 5%
of the patients IgE was directed against Api m 3 and/or Api m 10
only (16). The under-representation of Api m 3 and Api m 10 in
therapeutic venom preparations was additionally confirmed indi-
rectly by analyzing allergen sIgG4 in patients under VIT. While
VIT induced a robust sIgG4 response to Api m 1, Api m 2, and Api
m 4, no or only very little IgG4 induction could be observed to Api
m 3 and Api m 10.
Based on these findings, it is tempting to speculate that the rel-
ative lack of these two allergens in therapeutic venom preparation
may account for the reduced efficacy of VIT in bee venom-allergic
patients, a hypothesis that is currently under investigation. Pro-
vided that indeed different sensitization profiles to bee venom
allergens are associated with an increased risk of not being pro-
tected by VIT, one could envision different strategies to improve to
efficacy of VIT in these patients. Here improved methods of gen-
erating the therapeutic venom preparation may be developed to
circumvent the loss of individual allergens. Alternatively, existing
venom preparations could be enhanced by spiking with recom-
binant allergens that are under-represented or lacking. Finally,
generation of individual allergen cocktails for patient tailored
immunotherapy would be conceivable. The latter two options,
however, are highly unlikely, given the relatively small group of
patients that would benefit and the high regulatory requirements
for registrations of individualized immunotherapy products.
CONCLUSION
Advances in the characterization of Hymenoptera venoms offer
detailed insights into the molecular basis of toxicology and allergic
sensitization potential of individual venom components. Recom-
binant access and the capability to define the allergen glycosylation
allows for advanced strategies for differentiation of genuine dou-
ble sensitization and cross-reactivity as well as for avoidance of a
reactivity bias toward less relevant allergens in extracts. Applying a
growing panel of CCD-free species-specific as well as homologous
recombinant allergens, molecular diagnosis increasingly allows
for establishment of individual sensitization profiles. Such pro-
files also include the potential to follow the course of therapy, to
diagnose therapy-induced de novo sensitizations, opportunities to
adapt therapeutic intervention, and possibly to develop prognostic
markers for therapeutic success.
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